The Measurement of Health-related Quality of Life in Dermatology – Full Cardiff QoL References

Publications by A Y Finlay & Colleagues: complete list

Original Research

1987

Finlay AY, Kelly SE. Psoriasis – an index of disability. Clin Exp Dermatol, 1987; l2: 8-ll.

1989

Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol, 1989; 14: 194-198.

1990

Eun HC, Finlay AY. Measurement of atopic dermatitis disability. Annals of Dermatology, 1990; 2: 9-12.

Dooley G, Finlay AY. Personal construct systems of psoriatic patients. Clin Exp Dermatol, 1990; 15: 401-405.

Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol, 1990; 123: 751-756.

1992

Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol, 1992; 17: 1-3.

1993

Long CC, Funnell CM, Collard R, Finlay AY. What do members of the National Eczema Society really want? Clin Exp Dermatol, 1993; 18: 516-522.

Salek MS, Finlay AY, Luscombe DK, Allen BR, Berth-Jones J, Camp RDR, Graham-Brown RAC, Khan GK, Marks R, Motley RJ, Ross JS, Sowden JM. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. Br J Dermatol 1993; 129: 422-430.

1994

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use.
Clin Exp Dermatol, 1994; 19: 210-216.

1995

Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol, 1995; 132: 236-244.

Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol, 1995; 132: 942-949.

Kurwa H, Finlay AY. Dermatology inpatient admission greatly improves life quality. Br J Dermatol, 1995; 133: 575-578.

1996

Salek MS, Khan GK, Finlay AY. Questionnaire techniques in assessing acne handicap: reliability and validity study. Quality of Life Research, 1996;5: 131-138.

Blackford S, Roberts DL, Salek MS, Finlay AY. Basal cell carcinomas cause little handicap. Quality of Life Research, 1996; 5: 191-194.

Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporine in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol, 1996; 34: 1016-1021.

Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol, 1996; 7: 149-154.

Harris A, Burge SM, Dykes PJ, Finlay AY. Handicap in Darier’s disease and Hailey-Hailey disease. Br J Dermatol, 1996; 135: 959-963.

1997

Blackford S, Finlay AY, Roberts DL. Quality of life in Behcet’s Syndrome: 335 patients surveyed. Br J Dermatol, 1997; 136: 293.

Newton JN, Mallon E, Klassen A, Ryan TJ, Finlay A. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br J Dermatol, 1997; 137: 563-567.

1998

Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol, 1998; 138: 107-113.

Grosshans E, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M, Finlay AY, Soto P, Poncet M, Verschoore M, Clucas A.Evaluation of clinical efficacy and safety of adalpalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol, 1998; 139 (Suppl 52): 26-33.

1999

Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. BrJ Dermatol, 1999; 140: 672-676.

2000

Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, Finlay AY et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol, 2000; 142: 52-58.

Ayyalaraju RS, Finlay AY. Inpatient Dermatology: United Kingdom and United States similarities. Chapter in Dermatologic clinics: Inpatient dermatology. Eds: FA Kerdel, RS Kirsner, Dermatologic Clinics 2000; 18(3): 397-404.

Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000; 143: 979-982.

2001

Lewis-Jones MS, Finlay AY, Dykes PJ. The Infant’s Dermatitis Quality of Life Index. Br J Dermatol, 2001; 144: 104-110.

Touw CR, Hakkaart-Van Roisen L, Verboom P, Paul C, Rutten FFH, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144:967-972.

Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2001; 15: 137-139.

2002

Hermansen SE, Helland CA, Finlay AY. Patients’ and doctors’ assessment of skin disease handicap. Clin Exp Dermatology 2002; 27: 249-250.

Fivenson D, Arnold R J G, Kaniecki D J, Cohen J L, Frech F, Finlay A Y. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. J Managed Care Pharmacy 2002; 8 (5): 333-342.

2003

Salek M S, Finlay A Y. Quality of Life in patients with severe psoriasis receiving cyclosporin: a multi-centre study. J Applied Therapeutic Research 2003; 4: 3-10.

Holme S A, Mann I, Sharpe J L, Dykes P J, Lewis-Jones M S, Finlay A Y. The Childrens’ Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003; 148: 285-290.

Loo W-J, Diba V, Chawla M, Finlay A Y. Dermatology Life Quality Index: influence of an illustrated version.
Br J Dermatol 2003; 148: 279-284.

Finlay A Y, Salek M S, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206(4): 307-315.

Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kirsner R S, Kerdel F A. Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: A comparative study. JAAD 2003; 49: 249-254.

2004

Salek M S, Finlay A Y, Lewis J J C, Sumner M I. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral®). Quality of Life Research 2004; 13: 91-95.

Szepietowski J, Salomon J, Finlay A Y, Klepacki A, Chodynicka B, Marioneau N, Taieb C, Myon E. 
Dermatology Life Quality Index: Polish Version.
 Dermatologia Kliniczna 2004; 6: 63-70.

Dreno B, Finlay A Y, Nocera T, Verriere F, Taieb C, Myon E. CADI: Cultural and linguistic validation into French of an acne disability index,
Dermatology 2004; 208: 104-108.

Lewis V, Finlay A Y. Ten years experience of the Dermatology Life Quality Index (DLQI) J Investig Dermatol Symp Proc 2004; 9(2):169-180.

Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay A Y. DLQI scores in vitiligo: reliability and validity of the Persian Version.BMC Dermatology 2004; 4: 8.

2005

Katugampola R P, Hongbo Y, Finlay A Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. BJD 2005; 152: 1256-1262.

Hongbo Y , Thomas C L, Harrison M A, Salek M S, Finlay A Y. Translating the science of quality of life into practice: what do DLQI scores mean? JID 2005; 125: 659-664.

David S E, Ahmed Z, Salek M S, Finlay A Y. Does enough quality of life related discussion occur during dermatology outpatient consultations? BJD 2005; 153: 997-1000.

Krueger G G, Langley R G, Finlay A Y, Griffiths C E M, Woolley J M, Lalla D, Jahreis A. Patient-reported outcomes of psoriasis improvement with etanercept therapy; results of a randomized phase II trial. BJD 2005; 153: 1192-1199.

Finlay A Y. Current severe psoriasis and the Rule of Tens. BJD 2005; 152: 861-867.

Lewis V J, Finlay A Y. Two Decades Experience of the PDI. Dermatology 2005; 210: 261-268.

Smith SH, Anstey AV, Barker JNWN, Burren AD, Chalmers RJG, Chandler D, Finlay AY, Griffiths CEM, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists Guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.

2006

Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN, Erythropoetic protoporphyria in the UK: Clinical features and effect on quality of life. Br J Dermatol 2006; 155: 374-381.

Takahashi N, Suzukamo Y, Natamura M, Miyachi Y, Green J, Ohya Y, Finlay A Y, Fukuhara S. Japanese version of the Dermatology Life Quality Index : Validity and reliability in patients with acne. Health Qual Life Outcomes 2006: 4(1): 46 (e-pub).

2007

Basra M K A, Sue-Ho R, Finlay A Y.  The Family Dermatology Life Quality Index:  measuring the secondary impact of skin disease.  British Journal of Dermatology 2007; 156: 528-538 Erratum:  British Journal of Dermatology 2007; 156: 791

Katugampola R P, Lewis V J, Finlay A Y.  The Dermatology Life Quality Index:  assessing the efficacy of biological therapies for psoriasis.  British Journal of Dermatology 2007; 156: 945-950

Basra M K A, Finlay A Y.  The family impact of skin disease:  the Greater Patient concept.
British Journal of Dermatology 2007; 156: 929-937.

Eghlileb A M, Davies E E G, Finlay A Y.  Psoriasis has a major secondary impact on the lives of psoriasis family members and partners.  British Journal of Dermatology 2007; 156: 1245-1250

Misery L, Finlay A Y, Martin N, Boussetta S, Nguyen C, Myon E, Taieb C.  Atopic Dermatitis:  impact on the quality of life of patients and their partners.  Dermatology 2007; 215: 123-129

Salek S, Roberts A, Finlay A Y.  The practical reality of using a patient reported outcome measure in a routine dermatology clinic.  Dermatology 2007; 215: 315-319

2008

Davies E, Patel C, Salek M S, Finlay A Y.  Does ad-hoc quality of life discussion in inflammatory skin disease consultations reflect standardised patient reported outcomes?  Clinical and Experimental Dermatology 2008; 33: 16-21.

Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.
Br J Dermatol. 2008; 159: 997-1035.

Gollnick HP, Finlay AY, Shear N; Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008; 9: 279-84.

Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC, Hawk JL, Sarkany RP, McMullen E, Rhodes LE, Farr PM, Anstey AV.The quality of life of 790 patients with photodermatoses. Br J Dermatol. 2008;159:192-7.

Basra MK, Edmunds O, Salek MS, Finlay AY. Measurement of family impact of skin disease: further validation of the Family Dermatology Life Quality Index (FDLQI). J Eur Acad Dermatol Venereol. 2008; 22: 813-21.

Gollnick HP, Finlay AY, Shear N. Can we define acne as a chronic disease? Am J Clin Dermatol 2008; 9: 279-284.

Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.

2009

Finlay AY. The burden of skin disease: quality of life, economic aspects and social issues. Clin Med. 2009; 9: 592-4.

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009; 161: 987-1019.

Ingram JR, Martin JA, Finlay AY. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. Am J Clin Dermatol. 2009; 10: 229-37.

Eghlileb AM, Basra MK, Finlay AY. The psoriasis family index: preliminary results of validation of a quality of life instrument for family members of patients with psoriasis. Dermatology. 2009; 219: 63-70.

Golics CJ, Basra MK, Finlay AY, Salek MS. Adolescents with skin disease have specific quality of life issues. Dermatology. 2009; 218: 357-66.

Potter PC, Kapp A, Maurer M, Guillet G, Jian AM, Hauptmann P, Finlay AY. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009; 64: 596-604.

2010

Hajjaj FM, Salek MS, Basra MK, Finlay AY. Clinical decision making in dermatology: observation of consultations and the patients’ perspectives. Dermatology. 2010; 221: 331-41.

Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010;163(4):719-25.

Hajjaj FM, Salek MS, Basra MK, Finlay AY. Nonclinical influences, beyond diagnosis and severity, on clinical decision making in dermatology: understanding the gap between guidelines and practice. Br J Dermatol. 2010; 163: 789-99.

Hajjaj FM, Salek MS, Basra MK, Finlay AY. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice. J R Soc Med. 2010; 103: 178-87.

2011

Finlay AY. Practice Gaps. Dermatologists should better integrate quality-of-life measures to inform and improve clinical decision making: comment on “The impact of pruritus on quality of life”. Arch Dermatol. 2011; 147: 1157.

Aksoy B, Altaykan-Hapa A, Egemen D, Atakan N. Indicators of health quality in 154 Turkish patients with psoriasis. J Dermatol 2011; 38(6): 600-3

Bhatti Z, Salek M, Finlay A. Chronic diseases influence major life changing decisions: a new domain in quality of life research. J R Soc Med. 2011; 104: 241-50.

Bhatti ZU, Salek MS, Finlay AY. Major life changing decisions and cumulative life course impairment. J Eur Acad Dermatol Venereol. 2011; 25: 245-6; author reply 246.

2012

Pereira FR, Basra MK, Finlay AY, Salek MS. The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology. 2012; 225: 45-53.

Katugampola RP, Badminton MN, Finlay AY, Whatley S, Woolf J, Mason N, Deybach JC, Puy H, Ged C, de Verneuil H, Hanneken S, Minder E, Schneider-Yin X, Anstey AV. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. Br J Dermatol. 2012; 167: 901-13.

Finlay AY, Basra MK, Piguet V, Salek MS. Dermatology life quality index (DLQI): a paradigm shift to patient-centered outcomes. J Invest Dermatol. 2012; 132: 2464-5.

Finlay AY, Basra MK. DLQI and CDLQI scores should not be combined.
Br J Dermatol. 2012; 167: 453-4.

2013

Dodington SR, Basra MK, Finlay AY, Salek MS. The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application. Br J Dermatol. 2013; 169: 31-46.

Bhatti ZU, Salek S, Finlay AY. Concept of major life-changing decisions in life course research. Curr Probl Dermatol. 2013; 44: 52-66.

Bhatti ZU, Salek SS, Bolton CE, George L, Halcox JP, Jones SM, Ketchell IR, Moore RH, Sabit R, Piguet V, Finlay AY. The development and validation of the major life changing decision profile (MLCDP). Health Qual Life Outcomes. 2013; 11: 78.

Salek MS, Jung S, Brincat-Ruffini LA, Macfarlane L, Lewis-Jones MS, Basra MK, Finlay AY. Clinical experience and psychometric properties of the Children’s Dermatology Life Quality Index (CDLQI), 1995-2012.  Br J Dermatol. 2013 Oct;169(4):734-59.

Golics CJ, Basra MK, Finlay AY, Salek S. The impact of disease on family members: a critical aspect of medical care. J R Soc Med. 2013; 106 (10): 399-407.

Golics CJ, Basra MKA, Salek MS, Finlay AY. The impact of patients’ chronic disease on family quality of life: an experience from 26 specialties.  International Journal of General Medicine 2013; 6: 787-798.

Basra MK, Gada V, Ungaro S, Finlay AY, Salek SM. Infants’ Dermatitis Quality of Life Index (IDQoL): a decade of experience of validation and clinical application.
Br J Dermatol. 2013 Oct;169(4):760-8.

Finlay AY. The three dimensions of skin disease burden: ‘now’, ‘long term’ and ‘family’.  Br J Dermatol. 2013 Nov;169(5):963-4.

2014

Finlay AY.  Quality of life in dermatology: after 125 years, time for more rigorous reporting. Br J Dermatol 2014; 170: 4-6.

Golics CJ1,2, Basra MK2, Finlay AY2 , Salek S1on behalf of the Family Quality of Life Research Group.  The development and validation of the Family Reported Outcome Measure (FROM-16)© to assess the impact of disease on the partner or family member. Qual Life Res. 2014; 23: 317-26.

Bhatti ZU, Finlay AY, Bolton CE, George L, Halcox JP, Jones SM, Ketchell RI, Moore RH, Salek MS.  Chronic disease influences over 40 major life-changing decisions (MLCDs): a qualitative study in dermatology and general medicine.  J Eur Acad Dermatol Venereol. 2014 Oct;28(10):1344-55.

Finlay AY. Download the free DLQI Psoriasis 360 app. MIMS Dermatology 2014; 10 (4): 38.

2015

Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data. Dermatology. 2015;230(1):27-33.

Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA.  Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infectious Diseases. 2015 Feb;15(2):190-5.

Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GB, Misery L, Szabo C, Linder D, Sampogna F, Evers AW, Halvorsen JA, Balieva F, Szepietowski J, Romanov D, Marron SE, Altunay IK, Finlay AY, Salek SS, Kupfer J.

The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries.

J Invest Dermatol. 2015 Apr;135(4):984-91

 

Finlay AY. Patient-reported outcome measures in psoriasis: assessing

the assessments. Br J Dermatol 2015 May;172(5):1178-9.

 

Basra MK, Zammit AM, Kamudoni P, Eghlileb AM, Finlay AY, Salek MS.  PFI-14©: A Rasch Analysis Refinement of the Psoriasis Family Index.  Dermatology. 2015;231(1):15-23.

 

Campbell N, Ali F, Finlay AY, Salek SS. Equivalence of electronic and paper-based patient-reported outcome measures. Qual Life Res. 2015 Aug;24(8):1949-61.

 

Finlay AY, Salek SS, Piguet V. Measuring Family Impact of Skin Diseases: FDLQI and FROM-16.  Acta Derm Venereol 2015; 95: 1036

 

Finlay AY. Measuring quality of dermatology care from the patient’s perspective: how was it for you? British Journal of Dermatology 2015; 173: 884-885.

Finlay AY. ©Copyright: why it matters. British Journal of Dermatology 2015; 173: 1115-1116.

2016

van Geel MJ, Maatkamp M, Oostveen AM, de Jong EM, Finlay AY, van de Kerkhof PC, Seyger MM. Comparison of the Dermatology Life Quality Index and the Children’s Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years.  Br J Dermatol. 2016 Jan;174(1):152-7.

 

Stull DE, McBride M, Houghton K, Finlay AY, Gnanasakthy A, Balp M-M. Assessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth Modeling.  Advances in Therapy 2016; 33 (2): 214-224.

 

Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NAQuality of life impact of childhood skin conditions measured using the Children’s Dermatology Life Quality Index (CDLQI): a meta-analysis.  Br J Dermatol. 2016 Apr;174(4):853-61.

 

Nast A, Dréno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, Finlay AY, Haedersdal M, Lambert J, Layton A, Lomholt HB, López-Estebaranz JL, Ochsendorf F, Oprica C, Rosumeck S, Simonart T, Werner RN, Gollnick H. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1261-8.

 

Finlay AY. Principles of Measurement and Assessment in Dermatology. Part 2, Chapter 16, Rook’s Textbook of Dermatology. Edited by Christopher Griffiths, Jonathan Barker, Tanya Bleiker, Robert Chalmers & Daniel Creamer

Ninth Edition, 2016. ISBN 9781118441190.

 

Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY, Gottlieb AB. Psoriasis. Nature Reviews Disease Primers 2016; pp 16082,

2016; 2: 1-17.

 

2017

 

Harun NA, Finlay AY, Piguet V, Salek S. Understanding clinician influences and patient perspectives on outpatient discharge decisions: a qualitative study. BMJ Open 2017; 7(3): e010807.

 

Finlay AY, Salek MS, Abeni D, Tomás Aragonés L, van Cranenburgh OD, Evers AWM, Jemec GB, Linder D, Manolache L, Marrón SE, Prinsen CAC, Susitaival P, Chernyshov PV. Why quality of life measurement is important in dermatology clinical practice An expert-based Opinion Statement by the EADV Task Force on Quality of Life. J Eur Acad Dermatol Venereol 2017; 31 (3): 424-431.

 

Finlay AY. Quimp: a word meaning “quality of life impairment”. Acta Derm Venereol 2017; 97: 546-547.

 

Sampogna F, Abeni D, Gieler U, Tomas-Aragones L, Lien L, Titeca G, Jemec GEB, Misery L, Szabo C, Linder D, Evers1 AW, Halvorsen JA, Balieva F, Szepietowski J, Romanov DV, Marron SE, Altunay IK, Finlay AY, Salek SS, Kupfer J, Dalgard F.

Impairment of sexual life in 3485 dermatological outpatients from a multicentre study in 13 European countries. Acta Derm Venereol 2017; 97: 478-482.

 

Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, Piguet V. A systematic review of the use of quality of life instruments in randomized controlled trials of psoriasis. Br J Dermatol 2017; 176(3): 577-593.

 

Chernyshov PV, Tomas-Aragones L, Manolache L, Marron SE, Salek MS, Poot F, Oranje AP, Finlay AY. Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on Quality of Life. J Eur Acad Dermatol Venereol 2017; 31(4): 576-593.

 

Balieva F, Kupfer J, Lien L, Gieler U, Finlay AY, Tomás-Aragonés L, Poot F, Misery L, Sampogna F, van Middendorp H, Halvorsen JA, Szepietowski JC, Lvov A, Marrón SE, Salek MS, Dalgard FJ. The burden of common skin diseases assessed with the EQ5D™: a European multicentre study in 13 countries. Br J Dermatol. 2017 May;176(5):1170-1178.

 

Szabó C, Altmayer A, Lien L, Poot F, Gieler U, Tomas-Aragones L, Kupfer J, Jemec GBE, Misery L, Linder D, Sampogna F, Evers AWM, Halvorsen JA, Balieva F, Szepietowski J, Romanov D, Marron SE, Altunay IK, Finlay AY, Salek SS, Dalgard F.  Attachment styles of dermatological patients in Europe: a multicenter study in 13 countries. Acta Derm Vener 2017 Jul 6;97(7):813-818.

 

Higaki Y, Tanaka M, Futei Y, Kamo T, Basra MKA, Finlay AY. Japanese Version of the Family Dermatology Life Quality Index: translation and validation. Journal of Dermatology 2017; 44(8): 914-919.

 

Finlay AY. Broader concepts of quality of life measurement, encompassing validation. J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1254-1259.

 

Sampogna F, Finlay AY, Salek SS, Chernyshov P, Dalgard FJ, Evers AWM, Linder D, Manolache L, Marron SE, Poot F, Spillekom-van Koulil S, Svensson Å, Szepietowski JC, Tomas-Aragones L, Abeni D; European Academy of Dermatology and Venereology TaskForce on Quality of Life. Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments. J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1429-1439.

 

Atwan A, Piguet V, Finlay AY, Francis NA, Ingram JR. Dermatology Life Quality Index (DLQI) as a psoriasis referral triage tool.  Br J Dermatol. 2017 Oct;177(4):e136-e137.

 

Finlay AY, Kaplan AP, Beck LA, Antonova EN, Balp M-M, Zazzali J, Khalil S, Maurer M. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1715-1721.

 

Ali FM, Kay R, Finlay AY, Piguet V, Kupfer J, Dalgard F, Salek MS. Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Qual Life Res 2017; 26(11): 3025-3034.

 

Lesner K, Reich A, Szepietowski JC, Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GB, Misery L, Szabó C, Linder D, Sampogna F, Evers AWM, Halvorsen JA, Balieva F, Lvov A, Marron SE, Altunay IK, Finlay AY, Salek SS, Kupfer J.  Determinants of Psychosocial Health in Psoriatic Patients: A Multi-national Study.  Acta Derm Venereol 2017; 97: 1182–1188.

 

Ali FM, Johns N, Finlay AY, Salek MS, Piguet V. Comparison of the paper-based and electronic versions of  the Dermatology Life Quality Index: evidence of equivalence.

Br J Dermatol 2017; 117: 1306-15.

 

Finlay AY. Real-world effect of biologics on quality of life in psoriasis. Br J Dermatol 2017; 117: 1164-5.

 

2018

 

Basra MKA, Salek MS, Fenech D, Finlay AY. Conceptualization, development and validation of T-QoL© (Teenagers’ Quality of Life): a patient-focused measure to assess quality of life of adolescents with skin diseases. Br J Dermatol 2018; 178: 161-175.

Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Manolache L, Tzellos T, Sampogna F, Evers AWM, Dessinioti C, Marron SE, Bettoli V, van Cranenburgh OD, Svensson A, Liakou AI, Poot F, Szepietowski JC, Salek MS, Finlay AY. Quality of Life Measurement in Acne. Position Paper of the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS). J Eur Acad Dermatol Venereol. 2018; 32: 194-208.

Ali FM, Salek MS, Finlay AY. Two Minimal Clinically Important Difference (2MCID): a new twist on an old concept. Acta Derm Venereol 2018; 98: 715-717.

 

Marron SE, Tomas-Aragones L, Navarro-Lopez J, Gieler U, Kupfer J, Dalgard FJ, Lien L, Finlay AY, Poot F, Linder D, Szepietowski JC, Misery L, Jemec GBE, Romanov D, Sampogna F, Szabo C, Altunay IK, Spillekom-van Koulil S, Balieva F, Ali FM, Halvorsen JA, Marijuan PC.  The psychosocial burden of hand eczema: Data from a European dermatological multicentre study. Contact Dermatitis. 2018 Jun;78(6):406-412.

 

Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Br J Dermatol. 2018; 178: 1297-1307

 

Balieva FN, Finlay AY, Kupfer J, Tomas Aragones L, Lien L, Gieler U, Poot F, Jemec GBE, Misery L, Kemeny L, Sampogna F, van Middendorp H, Halvorsen JA, Ternowitz T, Szepietowski JC, Potekaev N, Marron SE, Altunay IK, Salek SS, Dalgard FJ. The role of therapy in impairing quality of life in dermatological patients: a multinational study.  Acta Derm Venereol 2018; 98; 563–569.

 

Dalgard FJ, Svensson Å, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, Misery L, Szabo C, Linder D, Sampogna F, Evers AWM, Anders Halvorsen J, Balieva F, Szepietowski J, Lvov A, Marron SE, Alturnay IK, Finlay AY, Salek SS, Kupfer J. Dermatologists across Europe underestimate depression and anxiety: results from 3635 dermatological consultations. Br J Dermatol. 2018; 179(2):464-470.

 

Ali FM, Johns N, Salek S, Finlay AY. Correlating the DLQI with psychiatric measures: a systematic review. Clinics in Dermatology 2017 (in press)

 

Brenaut E, Halvorsen JA, Dalgard FJ, Lars L, Balieva F,  Sampogna F, Linder D, Evers AWM, Jemec GBE, Gieler U, Szepietowski J, Poot F, Altunay IK, Finlay AY,  Salek SS,  Szabo C,  Lvov A,  Marron SE,  Tomas-Aragones L, Kupfer J, Misery L. The psychological comorbidities of prurigo in European patients: A multi-centre study in 13 countries. JEADV 2018 (in press).

 

Finlay AY, Sampogna F. What do scores mean?  Informed interpretation and clinical judgement are needed. Br J Dermatol 2018 (in press)

 

 

 

Review articles

Finlay AY. Psychological aspects of acne – an overview. Symposium Proceedings “Treating the Acne Patient: The Skin and the Psyche”. Barcelona, November 1988. Pennine Press, Cheshire, 1989.

Motley RJ, Phillips G, Finlay AY. How much disability is caused by acne? Chapter in “Acne and Related Disorders”. Ed Marks R, Plewig G. Martin Dunitz, London, 1989, p141-143.

Salek MS, Finlay AY, Khan GK, Luscombe DK. Quality of life measurement in patients with psoriasis. Chapter 48 in “Progress in Clinical Pharmacy”. Rational Use of Drugs. Proc of the 18th European Symposium on Clinical Pharmacy, Nijmegen, 1989. Editors Muller NF, Hekster YA. Amsterdam Medical Press, SDU Publishers, The Hague, 1989, p255-259.

Finlay AY. Acne : Pathogenesis, disability and treatment. Indian J Dermatol, Venereol Leprol, 1990; 56: 349-353.

Motley RJ, Finlay AY. Treat acne early and avoid disability. Mims Magazine, 1991; 18: 15.

Finlay AY. The social aspects of skin disease. Update, 1992; 44: 99-106.

Finlay AY. Quality of life impairment in atopic dermatitis and psoriasis. Clin Exp Perspectives in Sandimmune Therapy, 1992; 2: 10-11.

Finlay AY. Psychological aspects of psoriasis. Sandorama, 1992; 3: 4-8.

Finlay AY. Facing up to acne. Occupational Health, 1992; 44: 339-341.

Finlay AY. Acne Vulgaris: What are the psychological aspects? Medical Dialogue, 1992; 367: 2-3.

Finlay AY. Chair’s Summary: Disability from skin disease. Chapter in “Dermatology Progress and Perspectives. Proceedings of the 18th World Congress of Dermatology, New York, June 12-18, 1992”. Ed W.H.C. Burgdorf, S.I. Katz. Parthenon Publishing Group, New York, 1993; p1087-1089.

Finlay AY. Psychological impact of skin disease. Chapter in “Horizons in Medicine 4”, Editors CA Seymour, AM Heagarty. McGraw-Hill, London, 1993, p172-179.

Finlay AY. Effect of cyclosporin A on quality of life in psoriasis and eczema. J Dermatol Treat, 1994; 5 (Suppl 1): 513-515.

Finlay AY. Quality of Life Survey. Exchange, 1994; 73: 22.

Finlay AY. Coping with Psoriasis. BMJ, 1995; 310: 1673 (letter).

Elton B, Finlay AY. Psoriasis – it’s not a laughing matter. Dermatology in Practice, 1995, 3 (4), 5-8.

Finlay AY. Quality of life issues and economic burden of psoriasis and atopic dermatitis. Clin Drug Invest, 1995; 10, Suppl 1: 1-6.

Finlay AY. Quality of life: effects of photodamage. J Dermatol Treat, 1996; 7 (suppl 2): S9-S11.

Finlay AY, Ryan TJ. Disability and handicap in dermatology. Internat J Dermatol, 1996; 35: 305-311.

Finlay AY. Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol, 1996; 135: 509-515.

Finlay A Y. Evaluation of Quality of Life in Dermatology: application to psoriasis. Chapter in Epidemiology, Causes and prevention of skin disease. Eds J J Grob, R S Stern, R M Mackie, W A Weinstock. Blackwell Science, Oxford 1997.

Finlay AY. Dermatological Disability. Medicine, 1997; 25: 8: 6-7.

Finlay A Y. Quality of Life Measurement in Dermatology: a practical guide. Br J Dermatol 1997; 136: 305-314

Finlay AY. Dermatology Life Quality Index: initial experience of a simple practical measure. Chapter in: Care management of skin diseases: Life quality and economic impact. Editors: R Rajagopalan, E.F. Sherertz, R.T. Anderson. Marcel Dekker, New York, 1998 p85-94.

Finlay AY. Skin Disease Disability: measuring its magnitude. Keio Journal of Medicine, 1998; 47: 131-134.

Finlay AY. Quality of life assessments in dermatology. Seminars in Cutaneous Medicine and Surgery, 1998; 17: 291-296.

Finlay AY. Quality of life and its measurement. Chapter in Advances in the Effective Management of psoriasis. Editors: Griffiths C, Barker J. Royal Society of Medicine Press, London, 1999.

Finlay A Y. Dermatology patients: what do they really need? Clin Exp Dermatol 2000; 35: 444-450.

Finlay A Y. Psoriasis from the patient’s point of view. Arch Dermatol 2001; 137: 352-353.

Finlay A Y. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001. 45 (Suppl 1): S64-S66.

Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay AY, Leyden JJ, Shalita AR, Thiboutot D. Management of Acne. “A report from a Global Alliance to improve outcomes in acne.” J Am Acad Dermatol, 2003: 49 (Suppl. 1): S33-S35.

Working Group (including Finlay AY). Report on the enquiry into the impact of skin diseases on people’s lives. All Party Parliamentary Group on Skin, London, July 2003.

Finlay A Y, Burgdorf W H C. Quality of life measurement in atopic dermatitis in ‘Tacrolimus ointment’. Eds: T Ruzicka, S Reitamo. Springer, Berlin 2003, P237-254.

Griffiths C E M,, Dubertret L, Ellis C N, Finlay A Y, Finzi A F, Ho V C, Johnston A, Katsambas A, Lison A-E, Naeyaert J M, Nakagawa H, Paul C, Vanaclocha F. Ciclosporin in psoriasis clinical practice: An international consensus statement. British Journal of Dermatology 2004; 150 (Suppl 67): 11-23.

Finlay A Y. Quality of Life Indices. Indian J Dermatol Venereol Leprol 2004; 70: 144-149.

Cotterill J A, Finlay A Y. General aspects of treatment. Chapter 71 in Rook Textbook of Dermatology, Editors – T Burns, S Breathnach, N Cox, C Griffiths. Blackwell Science, Oxford, 2004.

Katugampola R P, Finlay A Y. Impact of skin diseases on quality of life. Chapter 2.7 in P Fritsch, W Bergdorf (Editors). EDF White Book, Skin Disease in Europe 2nd Edition Berlin 2005, ABW Wissenschaftverlag.

Lewis V J, Finlay A Y. A critical review of quality of life scales for psoriasis. Dermatol Clin 2005; 23(4): 707-716.

Lewis V J, Ortonne J-P. Patient satisfaction with psoriasis therapies: an update and introduction to biological therapy. J Cutan Med Surg 2004; 8(5): 310-320.

Finlay A Y. Research methodology in quality of life assessment. Chapter 9 in Psychodermatology, the psychological impact of skin disorders. Editors C Walker, L Papadopoulos. Cambridge University Press, Cambridge 2006.

Finlay A Y. The burden of atopic eczema. Chapter 4 in Handbook of Atopic Eczema, 2nd Edition. Eds J Ring, B Przybilla, T Ruzicka. Springer-Verlag, Berlin 2006 P31-36.

Finlay A Y. Uni-dimensionality of the DLQI – confirmed at last. Acta Dermato-Venereologica 2005; 85: 385.

Finlay A Y. The Dermatology Life Quality Index. MIMS Dermatology 2006; 2: 12.

Griffiths C E, Katsambas A, Dijkmans B A, Finlay A Y, Ho V C, Johnston A, Luger T A, Mrowietz U, Thestrov-Pedersen K. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol 2006; 155 (Suppl 2): 1-16.

Dalgard F, Finlay A Y.  Need and greed in dermatology:  disease and outcome measures in dermatological healthcare planning.  Dermatology 2006; 213: 279-283

Katugampola RP, Finlay AY. Impact of skin diseases on quality of life. Eur J Dermatol. 2007; 17: 102-6.

Finlay AY, Reich K. Outcome assessment and treatment goals. Expert Reviews in Dermatology 2008; 3 (4 Suppl 1) S39-40.

Yan H, Li W, Finlay AY. Measures of disease severity and life quality in patients with psoriasis. Int J Dermatol Venereol 2009; 35: 306-8.

Greaves MW, Munro CS, Finlay AY. Dermatology: the last 30 years – a rollercoaster ride. Clinical Medicine 2009; 9: 588-594.

Finlay AY, Smith CH. General aspects of treatment. Chapter 72 in Rook’s Textbook of Dermatology, 8th edition. Editors DA Burns, SM Breathnach, NH Cox, CEM Griffiths. 2010 Blackwell publishing, Oxford.

Bhatti ZU, Salek S, Finlay AY. Concept of major life-changing decisions in life course research. Current Problems in Dermatology 2013; 44: 52-66.

Katugampola RP, Finlay AY. Impact of skin diseases on quality of life. Editors J Barker, W Burgdorf. The Challenge of Skin Diseases in Europe. EDF White Book. 4th edition. ABW Wissenschaftsverlag, Berlin 2013, p23-24.

Basra M K A, Finlay A Y.  ‘Instruments of measurement of QoL in acne’ (p 551-562).  ‘Impact of Rosacea on the QoL’ (p 743-748). Chapters in Pathogenesis and treatment of Acne and Rosacea.  Editors:  Zouboulis C C, Katsambas A, Kligman A M.  Springer, Heidelberg 2014.

Katugampola R, Finlay AY.  Impact of skin diseases on quality of life. Chapter in: The Challenge of Skin diseases in Europe. EDF White book, 5th Edition. Editors: Harald Golnick, Jonathan Barker, Martine Bagot, Luigi Naldi. ABW Wissenschaftsverlag. Berlin 2017. pp33-35.

 

Katugampola R, Finlay AY. Livedo Reticularis. Chapter 40 in Treatment of Skin Disease: Comprehensive therapeutic strategies. 5th Edition. Editors M G Lebwohl, W R Heymann, J Berth-Jones, I Coulson. Elsevier 2018. Pp 457-459.

 

Finlay AY. Assessing and Scoring Life Quality. Chapter in Harper’s Textbook of Pediatric Dermatology, 4th edition. Editors: Peter Hoeger, Veronica Kinsler and Albert Yan. 2018.

 

 

QOL

Further Information

For general queries, technical aspects and permission to use:

E-mail: dermqol@cf.ac.uk

Other contacts:

Mrs Joy Hayes (financial aspects):
HayesJ@cf.ac.uk

Professor Andrew Y Finlay:
FinlayAY@cf.ac.uk

Address:
Department of Dermatology
Cardiff University School of Medicine
Heath Park, Cardiff
CF14 4XN
United Kingdom
Tel: +44 (0)29 2074 2884
Fax: +44 (0)29 2074 4321

FAQs

Quality of Life FAQs

Publications

Key References
Full Reference List